Phase 2 N=300 A Phase 2 Study of BTA798 in Asthmatic Adults With Symptomatic Human Rhinovirus Infection
Rhinovirus
Primary: Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21) Questionnaire — -9.12; -5.11 Scores on a scale — p=0.020
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=21 Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT
Hematological Malignancies
Primary: Incidence of Acute GVHD — 45.0 percentage of participants
Phase 2 N=79 Aspirin in Preventing Colorectal Cancer in Patients at Increased Risk of Colorectal Cancer
Colon Cancer · Precancerous Condition · Rectal Cancer
Primary: Change of a Spectral Biomarker for Colonic Carcinogenesis (Called Spectral Slope or SPEC) From Baseline to 3 Months. — 40.72; 37.54; 43.45; 37.52 micron^-1 — p=0.11
Phase 2 N=20 Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema
Diabetic Macular Edema · Non-proliferative Diabetic Retinopathy · Proliferative Diabetic Retinopathy
Primary: The Change in Visual Acuity (Number of ETDRS Letters). — 67.8; 71.9; 69.6; 72.9 ETDRS letters
Phase 2 N=50 Pilot Study Using Avastin and Gleevec to Treat the Progression of Intraluminal Pulmonary Vein Stenosis
Pulmonary Veno Occlusive Disease
Primary: Number of Patients With Survival at 48 Weeks — 42 Participants
Phase 2 N=159 A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia (CLL)
Primary: Objective Response Rate — 59.7; 52.8; 63.9 Percentage of Participants — p=0.4475
Phase 2 N=6 Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer
Adenocarcinoma of the Esophagus · Adenocarcinoma of the Gastroesophageal Junction · Diffuse Adenocarcinoma of the Stomach
Primary: Maximum Tolerated Dose (MTD) of Everolimus — 2.5 mg
Phase 2 N=65 Dimethyl Fumarate for Obstructive Sleep Apnea
Obstructive Sleep Apnea · OSA · Sleep Apnea
Primary: Mean Change in Apnea Severity as Measured by the Respiratory Disturbance Index (RDI) — -3.11; 10.2 respiratory events/hour — p=0.0124
Phase 2 N=27 Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy
Head and Neck Cancer
Primary: Objective Tumor Response Rate at 3, 6, and 12 Months — 0; 0; 12; 13 participants
Phase 2 N=226 Effectiveness of Antibiotic Delivery Via Bio-absorbable Sponge
Paranasal Sinus Disease
Primary: Rate of Infection — 113; 113 Participants
Phase 2 N=95 Bupropion in Helping Adults Stop Smoking
Bladder Cancer · Cervical Cancer · Esophageal Cancer
Primary: Prequit Change in Cigarettes Per Day — -2.6; -3.9 Cigarettes Per Day
Phase 2 N=40 Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer
Superficial Bladder Cancer
Primary: Incidence of High Grade-Recurrence Free Survival at 360 Days — 7; 7 Participants
Phase 2 N=19 Evaluate Rituximab in Obtaining PCR (Polymerase Chain Reaction) Negative Leukapheresis Product in Patients With Relapsed Follicular Lymphoma
Non-Hodgkins Lymphoma
Primary: Rate of PCR Negativity — 14 Participants
Phase 2 N=75 Safety and Immunogenicity of a Trivalent Group B Streptococcus Vaccine in Healthy Pregnant Women
GBS Disease · Streptococcus Agalactiae
Primary: Concentration of Serotype Ia GBS IgG Levels in Infant Serum at Delivery and at Days 42 and 90 of Age — 6.98; 0.24; 6.18; 0.39 µg/mL
Phase 2 N=121 Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139)
Lymphoma. Non-Hodgkin
Primary: Objective Response Rate (ORR) Per Independent Radiologic Review Committee (IRRC) Assessment — 10.3; 2.9 Percent of participants